Table 3 Comparison of gene expression between resistant and non-resistant cell lines for adenocarcinoma and squamous cell carcinoma [65], and H3K9K14ac during treatment with an HDAC inhibitor for NSCLC cell lines [85]
From: SFRP1 is a possible candidate for epigenetic therapy in non-small cell lung cancer
Gene expression | ||||
|---|---|---|---|---|
Adenocarcinoma | ||||
| Â | Â | P-value | Non-resistant cell lines | resistant cell lines |
 SFRP1 |  | 4.64 × 10 −4 | 611.06 | >92.60 |
 DKK3 |  | 6.73 × 10−2 | 263.27 | >30.59 |
Squamous cell carcinoma | ||||
 SFRP1 |  | 7.42 × 10 −3 | 304.53 | >49.53 |
 DKK3 |  | 4.61 × 10−1 | 261.38 | <506.25 |
Histone modification (H3K9K14ac) | ||||
| Â | Â | P-value | 0Â hours | 2Â hours |
|  | (A549) | 2.90 × 10 −2 | −1.29 | <−0.52 |
 SFRP1 | (H1299) | 4.06 × 10 −2 | −2.51 | <−1.85 |
|  | (CL1-1) | 8.71 × 10−1 | −1.38 | <−1.34 |
|  | (A549) | 6.19 × 10−1 | −1.17 | <−1.01 |
 DKK3 | (H1299) | 1.98 × 10 −3 | −1.70 | <−0.48 |
|  | (CL1-1) | 1.48 × 10−1 | −0.59 | >−1.13 |
|  | (A549) | 4.74 × 10−1 | −1.70 | <−1.37 |
 TACSTD1 | (H1299) | 1.51 × 10−1 | −2.61 | <−2.20 |
|  | (CL1-1) | 8.62 × 10−1 | −2.03 | >−2.09 |
|  | (A549) | 1.71 × 10 −3 | −2.44 | <−1.05 |
 SALL4 | (H1299) | 5.23 × 10−1 | −2.62 | >−2.86 |
|  | (CL1-1) | 1.03 × 10 −4 | 0.97 | >−0.59 |